LLY.SW

Eli Lilly and Company [LLY.SW] Stock Forecast

Q: What is Eli Lilly and Company stock symbol ?

Eli Lilly and Company is a US stock, located in Indianapolis of In and trading under the symbol LLY.SW

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

LLY.SW Stock Summary

Earnings have grown 19.56% per last year.

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Has a high level of debt. Debt-to-Equity ratio of 2.34 is considered high.

Earnings are expected to fall -100% next year

LLY.SW has less than 1 year of cash runway

In the News

LLY.SW Financial details

Company Rating

Strong Buy

Market Cap

670.29B

Income

5.24B

Revenue

34.12B

Book val./share

11.35

Cash/share

3.08

Dividend

4.52

Dividend %

0.76%

Employees

43K

Optionable

Shortable

Yes

Earnings

30 Apr 2024

P/E

107.98

Forward P/E

PEG

-75.17

P/S

18.45

P/B

48.01

P/C

224.03

P/FCF

-3588.47

Quick Ratio

0.58

Current Ratio

1.05

Debt / Equity

2.34

LT Debt / Equity

1.69

EPS (TTM)

5.63

EPS next Y

EPS next Q

EPS this Y

-15.98%

EPS next Y

EPS next 5Y

EPS last 5Y

2.08%

Revenue last 5Y

8.86%

Revenue Q/Q

-1.53%

EPS Q/Q

-3720.69%

SMA20

3.13%

SMA50

28.39%

SMA100

28.39%

Inst Own

Inst Trans

ROA

ROE

45%

ROC

0.16%

Gross Margin

79%

Oper. Margin

18%

Profit Margin

16%

Payout

79%

Shs Outstand

Shs Float

Target Price

52W Range

328.0-740.0

52W High

-6.76%

52W Low

+110.37%

RSI

Rel Volume

0.01

Avg Volume

2.68K

Volume

Perf Week

-1.43%

Perf Month

3.76%

Perf Quarter

Perf Half Y

27.78%

Beta

0.367

Volatility

5.25%, 26.6%

Prev Close

Price

690

Change

LLY.SW Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	23.97	26.9	31.22	31.54	35.94
Net income per share	4.98	6.79	6.15	6.9	5.52
Operating cash flow per share	5.19	7.13	8.01	7.83	4.47
Free cash flow per share	3.74	4.9	5.94	5.08	-3.32
Cash per share	2.62	4.04	4.31	2.44	3.08
Book value per share	2.8	6.18	9.9	11.77	11.35
Tangible book value per share	-8.16	-5.91	-2.68	-0.56	-1.03
Share holders equity per share	2.8	6.18	9.9	11.77	11.35
Interest debt per share	17.4	18.59	18.99	18.31	27.08
Market cap	108.18B	152.5B	230.29B	339.38B	570.19B
Enterprise value	121.65B	165.44B	243.36B	353.55B	592.6B
P/E ratio	23.32	24.62	41.26	54.35	108.81
Price to sales ratio	4.85	6.21	8.13	11.89	16.71
POCF ratio	22.37	23.46	31.72	47.91	134.48
PFCF ratio	31.06	34.11	42.75	73.77	-180.9
P/B Ratio	41.5	27.03	25.65	31.87	52.93
PTB ratio	41.5	27.03	25.65	31.87	52.93
EV to sales	5.45	6.74	8.59	12.39	17.37
Enterprise value over EBITDA	18.42	21.65	27.85	37.48	47.58
EV to operating cash flow	25.15	25.45	33.52	49.91	139.76
EV to free cash flow	34.92	37.01	45.17	76.85	-188.01
Earnings yield	0.04	0.04	0.02	0.02	0.01
Free cash flow yield	0.03	0.03	0.02	0.01	-0.01
Debt to equity	6.06	2.94	1.88	1.52	2.34
Debt to assets	0.4	0.36	0.35	0.33	0.39
Net debt to EBITDA	2.04	1.69	1.5	1.5	1.8
Current ratio	1.16	1.4	1.23	1.05	0.94
Interest coverage	12.42	16.85	18.71	21.49	22.49
Income quality	0.58	1.05	1.3	1.13	0.81
Dividend Yield	0.02	0.02	0.01	0.01	0.01
Payout ratio	0.52	0.43	0.55	0.57	0.78
Sales general and administrative to revenue	0.28	0.25	0.23	0.23	0.2
Research and developement to revenue	0.25	0.25	0.25	0.25	0.27
Intangibles to total assets	0.26	0.24	0.24	0.23	0.19
Capex to operating cash flow	-0.28	-0.31	-0.26	-0.35	-1.74
Capex to revenue	-0.06	-0.08	-0.07	-0.09	-0.22
Capex to depreciation	-1.1	-1.53	-1.21	-1.63	-4.84
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.02
Graham number	17.71	30.74	37.03	42.74	37.54
ROIC	0.23	0.23	0.22	0.24	0.24
Return on tangible assets	0.16	0.17	0.15	0.16	0.1
Graham Net	-30.5	-32.82	-30.55	-30.86	-40.9
Working capital	1.93B	4.98B	3.4B	896.3M	-1.57B
Tangible asset value	-7.6B	-5.39B	-2.43B	-504.2M	-982.6M
Net current asset value	-22.88B	-23.35B	-21.2B	-20.68B	-27.42B
Invested capital	6.06	2.94	1.88	1.52	2.34
Average receivables	5.66B	6.24B	7.53B	8.34B	9.95B
Average payables	1.31B	1.51B	1.64B	1.8B	2.26B
Average inventory	3.14B	3.59B	3.93B	4.1B	5.04B
Days sales outstanding	90.62	103.06	104.75	109.45	121.25
Days payables outstanding	108.64	106.95	83.38	106.29	133.94
Days of inventory on hand	246.68	264.95	193.96	237.27	297.52
Receivables turnover	4.03	3.54	3.48	3.33	3.01
Payables turnover	3.36	3.41	4.38	3.43	2.73
Inventory turnover	1.48	1.38	1.88	1.54	1.23
ROE	1.78	1.1	0.62	0.59	0.49
Capex per share	-1.45	-2.22	-2.07	-2.74	-7.79

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	8.07	7.71	9.24	10.56	9.85
Net income per share	2.14	1.49	1.96	-0.06	2.31
Operating cash flow per share	1.74	1.92	0.7	2.43	-0.33
Free cash flow per share	1.13	0.92	-0.23	-2.01	-2.07
Cash per share	2.44	4.07	3.14	2.77	3.08
Book value per share	11.76	12.4	12.3	12.47	11.35
Tangible book value per share	-0.56	0.15	0.19	0.49	-1.03
Share holders equity per share	11.76	12.4	12.3	12.47	11.35
Interest debt per share	18.03	21.03	21.05	22.55	26.72
Market cap	339.48B	306.35B	416.26B	481.88B	570.19B
Enterprise value	353.65B	321.69B	432.38B	499.67B	592.6B
P/E ratio	43.8	56.95	59.02	-2.1K	65.1
Price to sales ratio	46.49	44.02	50.08	50.73	60.96
POCF ratio	214.9	177.02	658.74	220.09	-1.83K
PFCF ratio	331.49	370.39	-2.04K	-265.98	-290.47
P/B Ratio	31.88	27.38	37.62	42.95	52.93
PTB ratio	31.88	27.38	37.62	42.95	52.93
EV to sales	48.43	46.22	52.02	52.6	63.36
Enterprise value over EBITDA	147.8	188.78	186.38	78.07	164.44
EV to operating cash flow	223.87	185.88	684.26	228.21	-1.9K
EV to free cash flow	345.33	388.93	-2.12K	-275.8	-301.89
Earnings yield	0.01	0	0	0	0
Free cash flow yield	0	0	0	0	0
Debt to equity	1.52	1.69	1.7	1.8	2.34
Debt to assets	0.33	0.36	0.34	0.35	0.39
Net debt to EBITDA	5.92	9	6.95	2.78	6.22
Current ratio	1.05	1.3	1.13	1.05	0.94
Interest coverage	21.86	14.53	17.67	3.61	23.27
Income quality	0.82	1.29	0.36	-38.14	-0.14
Dividend Yield	0	0	0	0	0
Payout ratio	0.46	0.76	0.58	-17.7	0.46
Sales general and administrative to revenue	0.23	0.25	0.23	0.19	0.16
Research and developement to revenue	0.27	0.29	0.28	0.25	0.27
Intangibles to total assets	0.23	0.21	0.2	0.19	0.19
Capex to operating cash flow	-0.35	-0.52	-1.32	-1.83	5.29
Capex to revenue	-0.08	-0.13	-0.1	-0.42	-0.18
Capex to depreciation	-1.48	-2.49	-2.28	-9.74	-4.26
Stock based compensation to revenue	0.01	0.02	0.02	0.02	0.01
Graham number	23.8	20.39	23.29	4.23	24.27
ROIC	0.06	0.04	0.06	0	0.08
Return on tangible assets	0.05	0.03	0.04	0	0.04
Graham Net	-30.85	-32.31	-35.08	-37.66	-40.9
Working capital	896.3M	4.8B	2.42B	1.01B	-1.57B
Tangible asset value	-504.2M	134.7M	166.9M	440.5M	-982.6M
Net current asset value	-20.68B	-21.06B	-22.33B	-23.6B	-27.42B
Invested capital	1.52	1.69	1.7	1.8	2.34
Average receivables	8.44B	8.79B	9.1B	9.77B	10.85B
Average payables	1.81B	1.97B	2.25B	2.45B	2.52B
Average inventory	4.07B	4.43B	4.67B	4.85B	5.34B
Days sales outstanding	105.49	116.67	99.3	98.2	109.08
Days payables outstanding	112.24	111.53	123.2	117.82	130.81
Days of inventory on hand	250.55	251.45	238.95	237.15	290.58
Receivables turnover	0.85	0.77	0.91	0.92	0.83
Payables turnover	0.8	0.81	0.73	0.76	0.69
Inventory turnover	0.36	0.36	0.38	0.38	0.31
ROE	0.18	0.12	0.16	-0.01	0.2
Capex per share	-0.61	-1	-0.93	-4.45	-1.74

LLY.SW Dividend History

LLY.SW Frequently Asked Questions

What is Eli Lilly and Company stock symbol ?

Eli Lilly and Company is a US stock , located in Indianapolis of In and trading under the symbol LLY.SW

What is Eli Lilly and Company stock quote today ?

Eli Lilly and Company stock price is $690 today.

Is Eli Lilly and Company stock public?

Yes, Eli Lilly and Company is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 2.68K
Market Capitalization 670.29B
Employee 43K
CEO Mr. David A. Ricks
Headquarters Indianapolis,IN,US
IPO Date 1998-07-17
Website https://www.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.